CAR T-cell Therapy Market by Brand (Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2), Indication (Lymphoma, ALL, AML, Multiple Myeloma) - Global Forecast to 2032

The CAR T-cell Therapy Market is projected to reach $51.6 billion by 2032, at a CAGR of 43.3% from 2025 to 2032. CAR T-cell therapy is a treatment modality where T cells are engineered. The engineered CAR T cell gets activated when it encounters an antigen on a cancer cell. Activated CAR T cells multiply, and cytokines and activated T-cells cause significant inflammation focused on the cancer cell resulting in cell death. Hence, this is a widely known therapy for cancer patients.

The growth of this market is driven by increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy may restrain the growth of this market. Additionally, a high scope in emerging economies, innovation in CAR T-cell therapies and manufacturing processes are creating opportunities for market growth. Moreover, the high treatment cost of therapy and the lack of skilled professionals are challenging factors for the market.

Increasing Cancer Prevalence Drives the Demand for CAR T-cell Therapy

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with 10 million deaths globally in 2020. Nearly 70% of cancer deaths occur in low & middle-income countries. According to GLOBACAN, the global number of new cancer cases will reach 24,044,406 in 2032 from 19,292,789 in 2020. When compared among the regions, in North America, the new cancer cases will reach 3,070,906 in 2032 from 2,556,862 in 2020, while in Europe, the new cancer cases will reach 4,919,893 in 2032 from 4,395,052 in 2020. In Asia, the number of new cancer cases will reach 11,889,569 in 2032 from 9,386,454 in 2020.

Click here to: Get a Free Sample Copy of this report

Cancer incidence is increasing globally due to unhealthy diets, tobacco use, alcohol consumption, sedentary lifestyles, exposure to carcinogens, obesity, and pollution. This increasing cancer incidence is also estimated to put a tremendous economic strain on various economies. Early detection and treatment are critical to reducing mortality and improving the chances of survival. Various forms of cancer treatment are available, such as surgery, chemotherapy, and radiotherapy; however, therapeutic advancements to boost the efficacy of cancer treatment have led to the development of CAR T-cell therapy. CAR T-cell therapy is a precision medicine in which the engineered CAR T-cells bind to an antigen on the cancer cells and kill them. Due to its efficacy, the therapy is fast becoming a standard cancer treatment. Hence, the increasing cancer incidence drives the demand for CAR T-cell therapy.

Key Findings of the CAR T-cell Therapy Market Study:

In 2025, the Yescarta (axicabtagene ciloleucel) Segment is Expected to Dominate the CAR T-cell Therapy Market

Based on drug type, in 2025, the Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-Cell Therapy market. Yescarta (axicabtagene ciloleucel) treatment has been proven effective over other treatments. The drug has high efficacy in treating cancer in people with high-grade B-cell lymphoma (HGBL), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal large B-cell lymphoma (PMBCL) that was not responding to earlier therapies. Hence, dominated the CAR T-cell therapy market.

In 2025, the CD Target Antigen Segment is Expected to Dominate the CAR T-cell Therapy Market

Based on target antigen, in 2025, the CD target antigen segment is expected to account for the largest share of the CAR T-cell therapy market. CD is expressed throughout the B-cell developmental phase to terminal differentiation into plasma cells. As this antigen is very helpful for determining malignancies, most therapies, clinical trials, and research studies are based on CD target antigens.

In 2025, the Lymphoma Segment is Expected to Dominate the CAR T-cell Therapy Market

Based on indication, in 2025, the lymphoma segment is expected to account for the largest share of the CAR T-Cell Therapy market. Lymphoma is a group of blood cancers that develop from abnormal white blood cells or lymphocytes. Due to the increased cases of lymphoma, there was a rise in the adoption of CAR T-cell therapy for treating lymphoma, contributing to the large share of this segment.

Asia-Pacific: Fastest-growing Regional Market

Based on geography, Asia-Pacific is slated to record the highest growth rate during the forecast period. The growth of this market is mainly driven by the large pool of patient population seeking cancer treatment, increasing prevalence of cancer, investments by the major players in the market, increasing government spending on healthcare, and growing disposable income of the population leading to improved access to cancer treatment.

Key Players

The key players profiled in the CAR T-cell therapy market report are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).

Scope of the Report:

CAR T-cell Therapy Market Size & Trend Analysis, by Drug Type

• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Carvykti (ciltacabtagene autoleucel)
• Other Brands

CAR T-cell Therapy Market Size & Trend Analysis, by Target Antigen

• CD
• BCMA
• HER2
• Other Target Antigens
  (Other target antigens include EGFR, GD2, MUC16, Lewis Y, and ROR1)

CAR T-cell Therapy Market Size & Trend Analysis, by Indication

• Lymphoma
• Acute Lymphoblastic Leukemia
• Multiple Myeloma
• Acute Myeloid Leukemia
• Other Indications
  (Other indications include pancreatic cancer, breast cancer, ovarian cancer, scleroderma, HIV/AIDs, and autoimmune diseases.)

CAR T-cell Therapy Market Size & Trend Analysis, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
• Latin America
• Middle East & Africa

Key questions answered in the report: